Adaptive trial designs could accelerate HIV vaccine development

In the past 12 years, four large-scale efficacy trials of HIV vaccines have been conducted in various populations. Results from the most recent trial—the RV144 trial in Thailand, which found a 31 percent reduction in the rate of HIV acquisition among vaccinated heterosexual men and women—have given scientists reason for cautious optimism. Yet building on these findings could take years, given that traditional HIV vaccine clinical trials are lengthy, and that it is still not known which immune system responses a vaccine needs to trigger to protect an individual from HIV infection.

To accelerate development, scientists working at and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, propose using adaptive clinical trial designs. These designs allow a trial to be modified in response to data acquired during the study. Such trials would rapidly screen out poor vaccine candidates, enable extended evaluation of promising candidates and provide key information on the immunological basis for HIV prevention.

In a paper appearing this week in Science Translational Medicine, the scientists review the four major HIV vaccine trials undertaken thus far and the scientific questions and challenges that remain. They describe what is needed to advance HIV vaccines through clinical trials and how adaptive clinical trial designs may accelerate identification of an effective HIV vaccine.

More information: L Corey et al. HIV-1 vaccines and adaptive trial designs. Science Translational Medicine DOI: 10.1126/scitranslmed.3001863 (2011).

Related Stories

How HIV vaccine might have increased odds of infection

date Nov 03, 2008

In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection. A new study by a team of researchers at the Montpellier ...

A world first: Vaccine helps prevent HIV infection

date Sep 24, 2009

(PhysOrg.com) -- In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving ...

Puzzling results from HIV vaccine trial

date Dec 03, 2007

A potential HIV vaccine that recently failed a clinical trial in the United States may increase some people's chance of catching the virus that causes AIDS.

Experimental aids vaccine now in production

date Nov 12, 2008

(PhysOrg.com) -- The advance towards a vaccine for HIV/AIDS has taken another step closer to realization. A vaccine, developed by Dr. Chil-Yong Kang and his team at the Schulich School of Medicine & Dentistry at The University ...

Consortium to design human trials of mosaic HIV vaccine

date Oct 18, 2010

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel ...

Recommended for you

HIV can spread early, evolve in patients' brains

date Mar 26, 2015

The AIDS virus can genetically evolve and independently replicate in patients' brains early in the illness process, researchers funded by the National Institutes of Health have discovered. An analysis of ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.